upgrad buy
upgrad buy pipelin trump competit
improv pipelin visibl proven driver med-tech multipl expans
view ew litig disput w/ settl ew pipelin like
becom investor primari focu next five month two signific data
releas risk aortic mitral repair like push ew multipl higher
view investor gain confid acceler growth result upgrad
ew buy neutral rais po
ew inexpens competit immin think lotu take
much share ew given strong feedback receiv
ew ultra devic think ultra much import investor realiz
pipelin
data ew european mitral trial studi pascal could come march may
european approv could come lastli ew us pascal trial requir six
month follow-up suggest approv could come earlier expect
work risk see survey insid suggest street much focus
potenti superior doctor long trial clean think low
risk market realiz full promis potenti
longer term see potenti materi upsid ep investor yet
model spend level come despit complet sever clinic trial
model ep growth acceler justifi new po
ep given ew premium high teen ep compound-annual-growth-rate
larg cap med-tech trade ep w/ earn growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
edward lifesci leader emerg
field transcathet heart valv replac
one visibl innov excit
market medic devic sector
ew heart valv busi gener
compani total revenu critic care
busi account total sale
almost attent focus
compani today due on-going pioneer
role develop transcathet heart valv
ew stand-alon tavr name
believ tavr stand alongsid coronari stent
core technolog catheter lab
futur ew stock signific run
past sever yr remain cautiou
primarili basi high valuat
estim next yr littl room
error risk data potenti earlier
competit launch litig risk limit
upsid current estim
risk bullish call ew obviou view ew trade high multipl
expect upcom risk trial high competit
immin ew sale europ slow last quarter
regard competit expect us ou outsid us approv lotu
edg time last data modul file fda octob work
suggest govern shutdown wont impact fda approv file also
fda allow repris iv studi begin suggest level comfort
off-set concern ew one excit pipelin
med-tech pipelin becom much visibl next
month releas risk tavr data releas data ew
pascal mitral valv repair trial europ spring either march pcr
may similar mitraclip pascal seem obviou give us
confid upcom data releas
experi increas pipelin visibl usual drive meaning multipl
expans believ investor clearli focus long term ew
recent less-than-perfect quarterli result littl impact stock
litig settl investor like look near term issu
focu primarili ew pipelin could mean
risk data come mitral repair data come
american colleg cardiolog meet march risk tavr data ew
present data us high risk trial also
chanc ew present data european mitral valv repair trial
pascal pascal data like present pcr
meet pari may year ew compani besid clip-
like devic treat mitral regurgit focu mitral opportun
thing know certainti clip-typ devic work see deep dive note
mitral opportun expect ew risk studi high
doctor convers suggest wall street much focus superior
doctor long ew risk trial clean think market realiz full
potenti believ risk legitim larg market see
survey
street may miss
sapien ultra import devic realiz view save
intervent cardiologist time minut min case eas use
time save histor meaning driver market share even els
equal one main reason overli concern earlier
expect fda approv lotu edg start repris
iv intermedi risk studi began week expect take share
ew
ew us trial look pascal dmr patient six month endpoint accord
ew compar two year trial could lead faster
expect approv pascal us earli given least
patient primari mitral regurg also secondari mitral regurg think
ew initi approv could lead signific revenu
lastli view ew could acceler earn growth given
first year spend like fall current lofti level
sale see basi point leverag street
current model model ep y/i growth street
model ep y/i growth risk mitral europ could
drive late revenu growth us mitral could nice increment
driver
sapien expand indic asymptomat sever
earli tavr sapien revolutionari sapien expand indic asymptomat sever
safeti efficaci trial mitraclip function mr
pivot trial pascal use dmr patient
ef trial pascal use tricuspid valv
commerci launch pascal clip fmr dmr eu
pivot trial ew trans-sept mitral replac devic
pivot trial pascal use fmr patient
less-invas complex aortic valv procedur
mitral tricuspid
mid think could come much earlier
complet trial enrol approv
 data present like late march may
continu global launch initi phase
tabl ew model tavr mitral organ growth margin ep
sg sale
 sale
confid risk
publish
chart mani tavr procedur done past year
chart tavr procedur done last month patient
would consid
note calcul result base state tavr volum per year doc state mix risk level doc impli total
procedur risk level get total procedur level risk sampl group
chart practice/cent bolu risk patient wait sidelin
tavr procedur get tavr implant partner posit clean larg
bolu low-risk patient
chart patient see sever aortic stenosi could consid low risk
chart given definit low risk evolv beyond st current
combin st
frailti
note figur base upon interpret estim impact longer answer
tabl extend answer given definit low risk evolv beyond st
gener st prom gener age lifestyl limit comorbid
patient frail signific comorbid hostil chest
st less
prior heart surgeri less minim comorbid
young comorbid
st condit contribut risk account st frailti
st frail
tabl extend answer given definit low risk evolv beyond st
gener st prom gener age lifestyl limit comorbid
younger patient low comorbid factor
would previous hesit send surgeri
st score frailti
st less
less minim comorbid previou heart intervent activ
anyon recov sternotomi
st fragil
less st risk
st score less
trial better understand defin patient low risk st best factor defin
patient low risk age patient better marker defin patient low risk
st less younger patient comorbid condit
st marker low risk patient
st score low frailti index major comorbid condit
high intermedi
st risk mortal
potenti complic risk tavr cx savr
st less yr old independ adl iadl liver diseas
life expect
less risk mace
less
mortal less
low frailti good rehab potenti low st risk
calcul risk plu eyebal offic addit young low risk patient differ entiti older low
chart posit clean big impact could trial tavr case
note figur base upon interpret estim impact longer answer
tabl extend answer posit clean big impact could trial
tavr case volum
think take addit long-term data assess tavr low-risk patient particularli younger patient
dp/dt aortic pressur higher bioprosthes gener even savr bioprosthes diminish longev
mild moder
huge amount think volum doubl
increas low risk trial registri mani patient alreadi get tavr
increas volum tavr pt
increas
probabl expand tavr low risk patient
signific impact patient assess tavr first
slightli due long team durabl unsur
huge increas patient want tavr dont want surgeri
increas
increas volum
gradual year tavr would becom standard care sever patient didnt cad requir
game changer tavr procedur among topic discuss patient
enorm impact expand
increas tavr case volum
depend durabl valv durabl tar valv similar durabl surgic valv year
increas total volum durabl shorter increas volum
low-risk patient go surgeri
larg
increas low risk patient want tavr tune
tabl extend answer posit clean big impact could trial
tavr case volum
think take addit long-term data assess tavr low-risk patient particularli younger patient
dp/dt aortic pressur higher bioprosthes gener even savr bioprosthes diminish longev
expect increas volum
signific increas case load per month
increas
signific lot patient go surgeri time
think volum would go howev miss analysi matter tavr
issu durabl vendor focus cathet profil gone thinner thinner leaflet
materi avail edward inspiri dri process valv think go set durabl standard
tavr need compet
po base ew ep discount back earli
target multipl premium peer trade earn think ew
trade signific premium peer due belief potenti mitral
downsid risk price object tavi market develop risk rel
street high expect competit risk relat ew core tavi busi
risk market opportun technolog could smaller
assum upsid risk price object potenti deeper penetr
market larger market opportun model untreat high low
moder risk patient seek tavi given less invas natur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
